Use of Ketamine in Clinical Practice: A Time for Optimism and Caution.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  JAMA psychiatry

• Publication date

  2017-04-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1001/jamapsychiatry.2017.0078PMID 28249064
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Toward an Evidence-Based, Operational Definition of Treatment-Resistant Depression: When Enough Is Enough.

  2017cited by this paper
• A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders

  2017cited by this paper
• NMDAR inhibition-independent antidepressant actions of ketamine metabolites

  2016cited by this paper
• Ketamine: NMDA Receptors and Beyond

  2016cited by this paper
• Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: A pilot randomised controlled trial

  2016cited by this paper
• Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.

  2014cited by this paper
• Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.

  2013cited by this paper
• Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.

  1994cited by this paper

• The Emerging Crisis in Non-Prescribed Ketamine Use: A Rapid Attenuation of Depression in Face of Abuse and "Chill-out" or Escapism Drug.

  2026cites this paper
• Oral prolonged-release ketamine in treatment-resistant depression - A double-blind randomized placebo-controlled multicentre trial of KET01, a novel ketamine formulation - Clinical and safety results.

  2024cites this paper
• Views on Using Psychoactive Substances to Self-Manage Functional Neurological Disorder: Online Patient Survey Results.

  2022cites this paper
• Ketamine treatment for depression: A model of care

  2021cites this paper
• The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence.

  2020cites this paper
• Rapid Anti-Depressant Relief by Ketamine: Exploring A Complex Mechanism of Action

  2019cites this paper
• NMDA Antagonists for Treatment-Resistant Depression.

  2019cites this paper
• The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An update on bipolar depression

  2019cites this paper
• Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists

  2018cites this paper
• Blood pressure safety of subanesthetic ketamine for depression: A report on 684 infusions.

  2018cites this paper
• Ketamine for Depression, 4: In What Dose, at What Rate, by What Route, for How Long, and at What Frequency?

  2017cites this paper
• Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight.

  2017cites this paper
• Ketamine metabolites with antidepressant effects: Fast, economical, and eco‐friendly enantioselective separation based on supercritical‐fluid chromatography (SFC) and single quadrupole MS detection

  2017cites this paper